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Abstract Reactive oxygen species (ROS) are implicated in the
pathogenesis of osteoarthritis (OA). However, little is known
about the antioxidant defence system in articular cartilage.
We investigated the expression and regulation of peroxiredoxin
5 (PRDX5), a newly discovered thioredoxin peroxidase, in hu-
man normal and osteoarthritic cartilage. Our results show that
human cartilage constitutively expresses PRDX5. Moreover, the
expression is up-regulated in OA. In£ammatory cytokines tu-
mour necrosis factor K and interleukin 1 L contribute to this up-
regulation by increasing intracellular ROS production. The
present study suggests that PRDX5 may play a protective
role against oxidative stress in human cartilage.
, 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Osteoarthritis (OA) is the most common form of arthritis
and is characterised by chronic pain and signi¢cant disability.
Although the aetiology of OA is multifactorial, the key patho-
logical feature of OA is articular cartilage degradation [1]. The
pathological processes of cartilage degradation, including the
molecular processes that impair cartilage homeostasis, are still
largely unknown.
Several studies have demonstrated that chondrocytes are
able to generate reactive oxygen species (ROS) under certain
conditions [2^4]. The over-production of ROS molecules in-
cluding superoxide (Oc32 ), hydrogen peroxide (H2O2), hydrox-
yl radicals (cOH) and nitric oxide (NOc) may contribute to the
degradation of cartilage matrix. ROS can inhibit proteoglycan
and hyaluronic acid syntheses [5], fragment hyaluronan [6]
and enhance matrix protein degradation [7]. ROS also dam-
age cell membranes [8] and induce apoptosis of synoviocytes
[9]. Although there is information regarding the pathological
role of ROS in cartilage degeneration, little is known about
the antioxidant defence system and particularly about any
ROS scavengers in articular cartilage. The redox status of
human chondrocytes in OA is also largely undetermined.
To prevent toxicity by ROS, mammalian cells possess a
well-coordinated antioxidant enzyme system. Examples of
antioxidant enzymes that have been well characterised are
the superoxide dismutases (SOD) which catalyse superoxide
to H2O2 [10]. SOD play a critical but limited role in detoxify-
ing ROS, as H2O2 can cause oxidative stress if the levels of
the H2O2 detoxi¢cation enzymes are insu⁄cient or depleted.
Catalase and glutathione peroxidases are widely investigated
H2O2-scavenging enzymes. Recently, a novel family of perox-
idases, the peroxiredoxins (PRDX), was identi¢ed in many
living organisms. Six isoforms of PRDX have been identi¢ed
in mammals [11^13], all of which participate directly in elim-
inating H2O2 and neutralising other oxidising chemicals [14].
A study on the crystal structure of human peroxiredoxin 5
(PRDX5), also known as PrxV/AOEB166/PMP20/ARC1
[12,15^17], suggested that PRDX5 may have a broader activ-
ity against ROS compared with other isoforms of PRDX and
other antioxidant enzymes [18]. We have previously shown
that the expression of PRDX5 is up-regulated in degenerative
human tendon [19]. The expression of this enzyme in human
cartilage, particularly in osteoarthritic cartilage, has not been
investigated.
To understand better the mechanisms by which human
chondrocytes are protected against oxidative stress, we inves-
tigated the expression of PRDX5 in normal and osteoarthritic
human cartilage, and investigated the regulation of PRDX5
expression in human chondrocytes. We were particularly in-
terested in determining if in£ammatory cytokines play any
role in the regulation of PRDX5 expression.
2. Materials and methods
2.1. Tissue collection and culture
Human tissue collection in this study was approved by the South
Eastern Sydney Area Health Service Ethics Committee, Australia.
Human osteoarthritic cartilage (n=4) was removed from knee joints
of patients with OA undergoing total knee-replacement surgery. Sig-
ni¢cant OA was identi¢ed by preoperative radiography. Normal hu-
man cartilage (n=4) was removed immediately adjacent to the inser-
tion site of supraspinatus tendon as part of the surgical procedure to
reattach the tendon to bone. Signi¢cant OA was excluded by plain
anterior^posterior and lateral radiographs of the shoulder, and by
arthroscopic examination of the glenohumeral joint prior to open
rotator culf repair.
For RNA and protein extraction, cartilage tissues were snap-frozen
in liquid nitrogen upon collection and stored at 380‡C until RNA
extraction and tissue homogenisation were performed. For tissue cul-
ture, cartilage explant discs were made using a 4-mm-diameter dispos-
able biopsy punch (SMS Inc., Columbia, MD, USA) with an average
thickness of 2 mm. Three discs were placed in each well of 24-well
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plates (1 ml ¢nal volume). Chondrocytes were isolated from cartilage
by collagenase digestion [20] and plated in 25-cm2 £asks (5U105)
containing Dulbecco’s modi¢ed essential medium (DMEM) supple-
mented with 10% foetal bovine serum. Primary chondrocyte mono-
layer cultures and cartilage explants were incubated at 37‡C in a 5%
CO2 humidi¢ed atmosphere. Culture medium was replaced with se-
rum-free DMEM for all experiments.
To mimic in vivo pathological conditions, tumour necrosis factor K
(TNFK) 100 ng/ml, and interleukin 1 L (IL-1L) 10 ng/ml (RpD Sys-
tem, Minneapolis, MN, USA) were added to explant and chondrocyte
cultures. Catalase (500 U/ml) (Sigma, St. Louis, MO, USA) was used
as an H2O2 scavenger and added to chondrocyte culture 2 h before
TNFK stimulation. Tissue and cells were harvested at 3, 6, 12, 24 and
48 h after the addition of TNFK or IL-1L for total RNA extraction,
protein preparation and intracellular H2O2 determination.
2.2. Northern blotting
Total RNA was isolated from human chondrocytes using Trizol
reagent (Life Technologies, Melbourne, Australia) following the man-
ufacturer’s instructions. Denatured RNA samples (20 Wg) were frac-
tionated by electrophoresis in a denaturing 1% (w/v) agarose gel,
transferred to a GeneScreen Plus nylon membrane (NEN Life Science
Products, Boston, MA, USA), cross-linked using an ultraviolet cross-
linker (Ultra-Lum, Carson, CA, USA), and hybridised with 32P-la-
belled human PRDX5 cDNA probe. The blots were subsequently
stripped and reprobed with 32P-labelled human L-actin cDNA. All
probes were radiolabelled by random priming (Promega, Sydney,
Australia).
2.3. Western blotting
Human cartilage tissue was ground to a ¢ne powder in liquid nitro-
gen using a mortar and pestle, and homogenised in ¢ve volumes of
Tris^HCl bu¡er (pH 7.4) containing a protease inhibitor cocktail
(2 Wg/ml leupeptin, 5 Wg/ml pepstatin A, 2 mg/ml of ethylenediamine
tetraacetic acid (EDTA)^Na2, 500 Wg/ml AEBSF and 1 Wg/ml E-64)
(Sigma). Chondrocyte lysate was prepared by sonication in the same
homogenisation bu¡er. Proteins in the tissue homogenates or cell
lysate were denatured by boiling for 5 min in 2% (w/v) sodium do-
decyl sulfate (SDS) sample bu¡er and fractionated by electrophoresis
on 12.5% (w/v) SDS^polyacrylamide gel. The fractionated proteins
were electrophoretically transferred to a polyvinylidene di£uoride
membrane, and the blots were blocked with 5% (w/v) non-fat dry
milk TTBS solution containing 25 mM Tris, pH 7.5, 150 mM
NaCl, 0.05% (w/v) Tween 20. After washing in TTBS, the blots
were incubated for 1 h with polyclonal anti-PRDX5 antibody [19]
at 1:2000 dilution, followed by horseradish peroxidase-conjugated
anti-rabbit secondary antibodies (Chemicon, Melbourne, Australia).
Immunoreactive bands were detected by enhanced chemiluminescence
reagents (Pierce, Rockford, IL, USA). The membranes were stripped
with Restore Western Blot Stripping Bu¡er (Pierce) and reprobed
using a rabbit anti-human actin antibody (Sigma) as a house-keeping
control. The net intensity of the PRDX5 band was analysed by Bio-
Rad Quantity One image quanti¢cation system (Bio-Rad, Hercules,
CA, USA). PRDX5 protein level was expressed by the ratio of the net
intensity of the PRDX5 band to actin band of the same sample.
2.4. Intracellular H2O2 assay
Intracellular H2O2 generation was assessed in chondrocytes by a
£ow cytometric technique based on the methods of Sattler et al.
[21], in which 2P,7P-dichloro-£uorescin-diacetate (DCF-DA) (Sigma)
was used. DCF-DA is a cell-permeable dye commonly used to mon-
itor intracellular changes in ROS (more speci¢cally for H2O2). DCF-
DA readily di¡uses into cells where it is hydrolyzed to the non-£uo-
rescent derivative 2P,7P-dichloro-£uorescin (DCF) and is trapped with-
in the cells. DCF becomes highly £uorescent when oxidised by either
H2O2 or superoxide. Cellular £uorescence intensity is directly propor-
tional to the level of intracellular H2O2 produced by the cells and can
be monitored by £ow cytometry. Chondrocytes were freed from cul-
ture £asks by trypsin^EDTA. Cells (106) were incubated with 5 WM of
DCF-DA for 5 min at 37‡C and subsequently washed twice in cold
phosphate-bu¡ered saline before analysis by a £ow cytometer (FAC-
Sort, Becton Dickinson System, San Jose, CA, USA) with Cell Quest
Software (Becton Dickinson). The £uorescence of oxidised DCF was
measured with an excitation wavelength of 488 nm and emission
wavelength of 525 nm. Mean £uorescence intensity (MFI) for 10 000
cells was recorded for each sample. Fluorescence relative variance
(FRV) was calculated for each sample (S) compared with control
(C; loaded cells without TNFK treatment): FRV= [(MFIðSÞ3
MFIðCÞ)/MFIðCÞ.
2.5. Statistical analysis
Comparison of PRDX5 expression in normal and osteoarthritic
cartilage was made by Mann^Whitney Rank Sum Test using Sigma-
Stat (Jandel Scienti¢c, San Rafael, CA, USA). A P value 6 0.05 was
considered statistically signi¢cant.
3. Results
3.1. PRDX5 protein is constitutively expressed in human
cartilage and up-regulated in osteoarthritic cartilage
A rabbit antibody was raised against recombinant human
PRDX5 [19]. With this antibody, PRDX5 protein expression
was readily detected by Western blot of cartilage tissue homo-
genates (Fig. 1). To semi-quantify the PRDX5 protein expres-
sion in both normal and osteoarthritic cartilage, all blots were
reprobed with an anti-actin antibody and the results were ex-
pressed as a density ratio of PRDX5:actin. It was observed
that osteoarthritic cartilage had more ¢brin tissue and less
cellularity than normal cartilage. Even if the same amount
of total protein were loaded for Western blotting, one would
expect less cellular protein in osteoarthritic cartilage than in
normal cartilage. Therefore, the normalisation of PRDX5
protein with actin is important for the semi-quanti¢cation.
Fig. 1 shows a signi¢cantly higher PRDX5 protein level in
osteoarthritic cartilage than in normal cartilage, suggesting
an up-regulation of PRDX5 in OA.
3.2. PRDX5 expression is regulated by in£ammatory cytokines
To explore the mechanisms by which the PRDX5 expres-
sion in human chondrocytes is regulated, we introduce in£am-
matory cytokines to the cartilage explant culture and primary
chondrocyte culture, as cytokines have been shown to be im-
plicated in OA. As shown in Fig. 2, TNFK and IL-1L up-
regulated PRDX5 protein expression in the cartilage explant
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Fig. 1. Expression of PRDX5 protein in human articular cartilage.
A: PRDX5 protein bands (upper panel) and actin bands (lower
panel) detected by Western blotting in normal (N) and osteoarthritic
cartilage (OA). B: Comparison of PRDX5 protein levels in normal
and osteoarthritic cartilage (n=4) by densitometry analysis. PRDX5
protein level was expressed by the ratio of the net intensity of the
PRDX5 band to the actin band of the same sample. Bars represent
meanUS.E.M. *P6 0.05 OA vs normal.
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culture 24 h after the cytokine challenge. At 48 h, the PRDX5
protein levels decreased to near baseline in TNFK-treated car-
tilage and below baseline in IL-1L-treated cartilage. A similar
phenomenon was observed in primary chondrocyte culture
(Fig. 3). Both PRDX5 mRNA and protein expression started
to increase 3 h after TNFK stimulation, and reached their
peak levels at 12 and 24 h. The protein level returned to base-
line at 48 h, while the mRNA level remained high.
3.3. H2O2 might be an important mediator for the PRDX5
up-regulation in human chondrocytes
Cytokines can induce intracellular H2O2 production in
chondrocytes. We hypothesised that the increased PRDX5
expression in stimulated chondrocytes was a cellular response
to intracellular £ux of H2O2. To test this hypothesis, intra-
cellular H2O2 induction was measured using a £ow cytometric
technique. Catalase was introduced to the chondrocyte culture
system to test if scavenging H2O2 would a¡ect the PRDX5
expression level. As shown in Fig. 4A, the intracellular H2O2
level in cultured human chondrocytes started to rise 3 h after
a TNFK challenge, reached its peak at 6 h, and started to
decline at 12 h when the PRDX5 protein expression reached
its peak (Fig. 4B). The addition of catalase to the chondrocyte
culture prior to exposure to TNFK signi¢cantly inhibited
TNFK-induced intracellular H2O2 production (Fig. 4A), as
well as the enhanced PRDX5 protein expression (Fig. 4B, at
12 and 24 h), suggesting that H2O2 might be an important
mediator for the cytokine-induced PRDX5 up-regulation in
human chondrocytes.
4. Discussion
Articular chondrocytes, embedded in an avascular matrix,
are exposed to a low partial oxygen pressure and exhibit a
predominantly anaerobic metabolism [22]. Accordingly, the
ROS defence mechanisms in articular chondrocytes are gen-
erally weak and chondrocytes are susceptible to attacks by
ROS. However, chondrocytes have the potential to increase
their antioxidant status. Previous studies on chondrocytes
antioxidant mechanisms have shown that human chondro-
cytes constitutively express SOD and catalase [23]. Our study
provides the ¢rst evidence that human chondrocytes also ex-
press PRDX5 and the expression is signi¢cantly higher in
osteoarthritic cartilage compared with normal cartilage.
To explore the regulatory mechanisms of the PRDX5 ex-
pression, we introduced the in£ammatory cytokines TNFK
and IL-1L to cartilage explant cultures and primary chondro-
cyte cultures, as these cytokines have been shown to stimulate
chondrocyte ROS production [3,24] and to be implicated in
OA [25]. Our results demonstrate that IL-1L and TNFK are
important modulators of PRDX5 up-regulation. During the
time course observation of PRDX5 expression, we noted a
discrepancy between the PRDX5 mRNA and the protein lev-
els in TNFK challenged chondrocytes. Indeed, the PRDX5
protein level returned to baseline 48 h after TNFK stimula-
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Fig. 2. E¡ects of TNFK and IL-1L on PRDX5 protein expression in
human articular cartilage explant culture. Cartilage explants from
OA patients were precultured with TNFK (100 ng/ml; panel A) or
IL-1L (10 ng/ml; panel B) for the indicated times, and subject to
Western blot analysis using anti-PRDX5 and anti-actin antibodies
as described in Section 2.3.
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Fig. 3. E¡ects of TNFK on PRDX5 mRNA and protein expression
in cultured human articular cartilage chondrocytes. Chondrocytes
isolated from OA cartilage were precultured with TNFK (100 ng/ml)
for the indicated times. A: PRDX5 mRNA was detected by North-
ern blot analysis. B: PRDX5 protein expression was analysed by
Western blot.
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Fig. 4. E¡ect of catalase and/or TNFK on chondrocyte H2O2 pro-
duction and PRDX5 protein expression. A: Flow cytometric analy-
sis of intracellular H2O2 production by chondrocytes treated with
TNFK (100 ng/ml) or TNFK+catalase (500 U/ml) for the indicated
times. Catalase was added to culture 2 h before the addition of
TNFK. B: Western blot analysis of PRDX5 protein from chondro-
cytes treated as above. Results were representatives of three separate
experiments using chondrocytes isolated from three OA cartilages.
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tion, while the mRNA level remained high (Fig. 3). This may
be due to a translational block for the synthesis of PRDX5
protein, which may have happened 48 h after initial PRDX5
up-regulation as a feed-back protection mechanism, as phys-
iological levels of ROS are essential for many biochemical
processes, including signal transduction [26], cell di¡erentia-
tion and immunity [27]. Translational regulation has been
reported in many mammalian cells and is believed to be re-
sponsible for the discrepancy between mRNA and protein
levels [28,29]. More experiments are necessary to de¢ne the
translational regulation PRDX5 protein in human chondro-
cytes.
The pathways by which PRDX5 is up-regulated in OA are
not yet known. It is possible that the up-regulation of PRDX5
is a response to increased levels of ROS in OA, as there is
increasing evidence showing that over-production of ROS is
implicated in the pathogenesis of OA [4,7,30,31]. Our study
has shown that a TNFK/IL-1L challenge signi¢cantly increases
intracellular H2O2 production, followed by enhanced PRDX5
expression. When the H2O2 scavenger catalase was introduced
into the primary chondrocyte culture, intracellular H2O2 was
inhibited and this was accompanied by the inhibition of
PRDX5 protein expression, suggesting that H2O2 might be
an important mediator for the cytokine-induced PRDX5 up-
regulation.
The signi¢cantly increased expression of PRDX5 in OA
may act as a protection to cartilage against ROS-induced oxi-
dative damage. Increased SOD activity has been reported in
OA [32]. Dismutation of the anion superoxide to H2O2 by
SOD is a well-described defence mechanism against oxidative
stress at the cellular level. However, reduction of H2O2 by the
Fenton reaction to the highly toxic hydroxyl radical can be, in
some circumstances, even more harmful to the cell. H2O2
detoxifying enzymes, including PRDX5, can metabolise and
eliminate H2O2, partially avoiding the conversion of H2O2 to
hydroxyl radical. Among the H2O2 detoxifying enzymes, cat-
alase is known to be present only in peroxisomes [33] ; gluta-
thione peroxidase is restricted to the mitochondrial intermem-
brane space in very limited amounts [34] ; PRDX5, however, is
present in a broader range of intracellular locations, including
mitochondria, peroxisomes and cytosol [12]. The functional
signi¢cance of PRDX5 localisation in organelles needs further
investigation.
In conclusion, our study has demonstrated that the antioxi-
dant enzyme PRDX5 is constitutively expressed in human
chondrocytes. The expression is up-regulated in OA. In£am-
matory cytokines TNFK and IL-1L may be responsible for
this up-regulation via the stimulation of intracellular H2O2
production. PRDX5 may play a protective role against oxi-
dative stress involved in the pathogenesis of OA, and may
have therapeutic value in the prevention and treatment of OA.
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